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A B S T R A C T
Orally inhaled drug products (OIPs), such as corticosteroids and bronchodilators, are at the
forefront of asthma and chronic obstructive pulmonary disease treatments, two diseases
that afflict worldwide populations. Introducing generics of these products is essential, as
the pricing of these medications remain a barrier to adequate patient care. Currently, there
is no consensus between regulatory bodies as to the bioequivalence and equivalence re-
quirements of OIPs that are intended for local action in the lungs.This manuscript critically
reviews these requirements and presents future directions for clinicians, scientists, and regu-
lators to consider to optimize the development and approval of OIPs.
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Drug delivery directly to the lung of patients with airflow ob-
structions allows the delivery of relatively small doses of drug
directly to the airway achieving high local concentrations, while
minimizing systemic adverse drug effects [1]. Inhalers are most
commonly prescribed in the treatment of asthma and chronic
obstructive pulmonary disease (COPD) [2].
Asthma has a prevalence ranging from 1 to 18% and affects
approximately 300 million individuals worldwide [3]. Inhaled
corticosteroids (ICS), such as fluticasone, are one of the cor-
nerstones in the treatment of moderate to severe asthma [4].
They play a critical role in the long-term control of asthma
through their anti-inflammatory effects.They have been shown
to reduce asthma symptoms [5], improve quality of life [5],
improve lung function [5], decrease airway hyper responsive-
ness [6], control airway inflammation [7], reduce the frequency
and severity of exacerbations and reduce asthma-related mor-
tality [8].
Inhaled bronchodilators are also used in the treatment of
asthma [4] and are central in the treatment of patients with
COPD [9]. COPD has a prevalence ranging from 7.8 to 19.7%
world-wide, with a range of 3 to 11% among never smokers
[10]. The relaxation of airway smooth muscles that lead to
bronchodilation can be achieved by inhibiting acetylcholine sig-
naling via muscarinic M3 receptors expressed on airway smooth
muscle. This can be performed with a muscarinic antagonist
(e.g., tiotropium) or by stimulating beta-2 adrenoceptors with
a beta-2 agonist (e.g., salmeterol) [9].
* Corresponding author. Learn and Confirm Inc., 3630 Bois Franc, St-Laurent, QC H4R 3K9, Canada.Tel.: +1 514 373 5346; fax: +1 514 373 5346.
E-mail address: murray.ducharme@learnandconfirm.ca (M.P. Ducharme).
Peer review under responsibility of Shenyang Pharmaceutical University.
http://dx.doi.org/10.1016/j.ajps.2015.08.006
1818-0876/© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 4 6 1 – 4 7 1
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /a jps
HOSTED BY
ScienceDirect
In light of the critical role of ICS and inhaled bronchodilators
in the treatment of asthma and COPD, it is not surprising that
there is considerable interest in developing new combina-
tions of existing products, follow-ons and/or generic products
of existing ICS and inhaled bronchodilators.The use of generic
drugs in general is on the rise, accounting for 51% of prescrip-
tions in 2002 and 67% in 2007 in the US [11]. Recent estimates
indicate generic drugs account for approximately 80% of all
retail prescriptions dispensed in the US [12], and 66% in Canada
[13]. These growing trends, coupled with the urgent need to
relieve the economic burden of prescription drugs on pa-
tients and healthcare providers, force us to reconsider how the
drug development of generic ICS and inhaled bronchodilators
can be improved to bring such products to market in a safe
and timely manner. This puts additional pressure on innova-
tive companies to bring new products on the market as their
existing ones become preys to generic competition.With new
products costing an average of one to two billion dollars [14],
companies are not only developing new products entirely but
have also repositioned old products by introducing new and
improved devices (e.g., Diskus® line of products) or combina-
tion products (e.g., Advair®).
The aim of this manuscript is to review current regulatory
recommendations for highly regulated regions (e.g., Health
Canada (HC), US Food and Drug Administration (FDA), Euro-
pean Medicines Agency (EMA)) for the development of follow-
on and/or generic inhaler products, critically examine
assumptions and principles that underlie some of these rec-
ommendations, focusing on pharmacological principles, and
suggest other approaches that may be considered in the future.
2. General bioequivalence requirements for
OIPs: local vs systemic action
Clinical regulatory requirements to fulfill in order to obtain an
approval for a generic or follow-on drug product typically
depend first on the relationship between the systemic
circulation and the assumed site of activity of the active phar-
maceutical ingredient (API). For drug products reaching
first the systemic circulation and then distributing to the theo-
retical site(s) of activity via the systemic circulation,
pharmacokinetic (PK) studies indicating equivalence in terms
of systemic exposure (e.g., typically Cmax and AUC) between a
follow-on/generic formulation and a reference one will ensure
that their safety and efficacy will be similar because a similar
systemic exposure will result in similar exposures at the theo-
retical site(s) of activity. For these products, a generic version
would be demonstrated to be bioequivalent to a reference
product using one or more PK equivalence studies. A theo-
retical example of such a product would be a potential generic
inhaled insulin product, as insulin will reach its sites of ac-
tivity via the systemic circulation.
On the other hand, a drug product for which its API is de-
livered from a formulation at its intended site(s) of activity
before reaching the systemic circulation is typically called a
“locally acting” product. For these products equivalence in terms
of systemic exposure may not ensure “local” exposure equiva-
lence and therefore a PK equivalence study may not suffice to
ensure similar efficacy and safety. Examples of “locally” acting
products within the lungs include inhalers for COPD and
asthma, such as albuterol, budesonide, ipratropium, tiotropium,
fluticasone and salmeterol.
3. Current regulatory requirements for
generic submissions of “locally acting”
inhaled products
3.1. North American requirements (FDA and HC)
Although clear guidelines exist in the U.S. with respect to the
conduct of bioequivalence (BE) studies of OIPs [15], presently
there is no general guideline on how to establish BE of OIPs.
In the US, the FDA has issued a general guidance docu-
menting the CMC requirements [16], and three individual
product BE guidances: one for budesonide suspension inhaler
[17], one for albuterol sulfate metered dose inhaler [18], and
one for the fluticasone propionate/salmeterol xinafoate dry
powder inhaler [19].
Despite the absence of an FDA guidance document on the
BE of OIP in general, scientific and regulatory considerations
for demonstrating BE between dry powder inhalers (DPI) have
been proposed [20], and recently reviewed [21]. The FDA has
developed an aggregate weight-of-evidence approach which
utilizes in vitro studies, PK equivalence studies, and pharma-
codynamic (PD) or clinical endpoint (CE) studies (also called
Therapeutic Equivalence (TE) studies), to establish BE of in-
halation products [21]. Equivalence in all categories of interest
is required [22]. As such, a generic formulation of a reference
inhaler product needs to demonstrate that 1) its device will
be judged to be equivalent in a patient’s hand, 2) that its in
vitro characteristics and performance in terms of emitted dose
and aerodynamic particle size distribution is equivalent, 3) that
its systemic PK exposure is equivalent, and finally that 4) its
clinical efficacy is equivalent.
At the present moment, the requirements for HC are very
similar to those of the US FDA. HC also demands that equiva-
lence be demonstrated in terms of device, in vitro characteristics
and performance, systemic PK exposure, and clinical efficacy.
In Canada, the requirements are specified in three guid-
ances, one specifying the requirements for second entry short-
acting beta-2 agonist metered dose inhalers [23], one focusing
on the in vitro requirements for nasal and inhalation prod-
ucts [24], and finally a draft guidance specifying what studies
would be needed to prove similar clinical safety and efficacy
[25]. This last guidance was however recently pulled from the
HC website, possibly an indication that a new updated version
is forthcoming. One difference with the FDA is that HC is less
prescriptive in terms of study design for the clinical equiva-
lence study and sponsors can theoretically use different designs
as long as they can prove to the agency that it will ensure
equivalent efficacy between the generic and reference inhaled
products [25].
3.2. European requirements (EMA)
Many guidelines exist to describe what the requirements are
for EU submissions. The guideline CPMP/EWP/4151/00 Rev.1
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covers the overall requirements and specifies the needed clini-
cal studies [26], while the guideline EMEA/CHP/QWP/49313/
2005 Corr. specifies what the in vitro requirements are [27].
The EMA guidelines allow the theoretical approval on the
basis of in vitro data only provided that results are all favor-
able. If an applicant cannot demonstrate complete in vitro
similarity, or if the applicant’s product is deemed too different
from the reference product, then PK studies to establish equiva-
lent safety and efficacy are suggested. Equivalence in terms of
efficacy is typically recommended to be established via a PK
systemic exposure equivalence study where charcoal is ad-
ministered to block GI absorption so that only the exposure of
theAPI absorbed via the lung is compared. Equivalence in terms
of safety is done via a PK systemic exposure equivalence study
but where charcoal is not administered, so that the total sys-
temic exposure of the generic versus the reference product are
compared, not just what is absorbed via the lung. Should PK
studies fail or should they be considered to not address the
specific in vitro failures of the test product, clinical studies are
then needed to establish equivalent safety and efficacy. One
important difference versus FDA or HC is that in Europe, OIPs
are not approved as generic submissions but as hybrids, and
they are not automatically substituted. Substitution is deter-
mined nationally. Very few international approvals appeared
to have been granted since the issuing of the general guid-
ance. The publicly available assessment reports suggest that
not all regulators adhere strictly to all parts of the guideline.
It can be appreciated that the device and in vitro require-
ments are generally aligned between these three regulatory
jurisdictions, but they differ substantially in how similar clini-
cal safety and efficacy must be demonstrated. The general
requirements are summarized and contrasted in Table 1.
We can see that the requirements for HC and US submis-
sions are relatively similar, while they are very different in the
EU. For this latter one, definite proof of device and in vitro simi-
larity can theoretically suffice for a “hybrid” submission,
although it appears in practice that EU regulators are feeling
more comfortable if sponsors do a minimum of two Phase I
PK studies, with and without charcoal concomitant adminis-
tration.A “practical” requirements table can be constructed (see
Table 2) using the example of the Advair Diskus® product.
4. Current controversial aspects related to
locally acting inhaled products
4.1. The need for concomitant charcoal administration in
PK equivalence studies
One study design aspect that not all regulatory agencies agree
with is the requirement by the EMA to perform two PK equiva-
lence studies if all in vitro tests are not conclusive of equivalence;
one study with and one study without charcoal. The PK study
without charcoal is performed to prove “safety equivalence”
as the total systemic exposure from both the lung and gut ab-
sorptions will be measured.The charcoal PK study is performed
to prove “efficacy equivalence” and will only measure the “lung
absorption exposure” as the absorption from the gut will be
inhibited by the charcoal. The theory for the charcoal study is
that the systemic exposure from this study serves as a surro-
gate for the local lung absorption and exposure. This however
ignores the fact that efficacy can also be due to systemic free
drug exposure resulting from the part of the inhaled dose that
is swallowed and absorbed through the gut. Of course this will
be virtually nil for low oral gut bioavailability and highly protein
bound drugs like fluticasone (fluticasone has 1% oral gut
bioavailability and is 99% plasma protein bound [28]), but it may
be somewhat important for others such as albuterol or
Table 1 – General regulatory agency requirements for demonstrating bioequivalence of generic OIPs.
US FDA HC EU Notes




“Hybrid” submission No specific declaration of
equivalence or
interchangeability in
Europe for these products
Device similarity Device must be deemed to
be “similar” to the one used
by the US marketed
reference product (URP)
Device must be deemed to
be “similar” to the one used
by the Canadian marketed
reference product (CRP)
Device must be deemed to
be “similar” to the one used
by a European marketed
reference product (ERP)
Similar requirements for all
three jurisdictions
In vitro performance Device must have similar in
vitro performance versus
the URP
Device must have similar in
vitro performance versus
the CRP
Device must have similar in
vitro performance versus
the ERP
Similar requirements for all
three jurisdictions, but in
the EU complete in vitro
similarity can remove
clinical requirements
Similar safety Generic Test product must
show similar systemic
exposure in a PK study
versus the URP
Generic Test product must
show similar systemic
exposure in a PK study
versus the CRP
Generic Test product must
show similar systemic
exposure in a PK study
versus the ERP
EU does not theoretically
need any PK study if in vitro
requirements are
completely met
Similar efficacy Generic Test product must
show similar efficacy in a
Therapeutic Equivalence
(TE) study with Clinical
Endpoint (CE) versus the
CRP and must be superior
to placebo
Generic Test product must
show similar efficacy in a
TE study with CE versus the
CRP and must be superior
to placebo
Generic Test product must
show similar systemic
exposure in a PK study
versus the ERP when
administered with
activated charcoal to block
systemic absorption
EU does not need
theoretically any PK or TE
study(ies) if in vitro
requirements are
completely met
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levalbuterol, drugs that are very little plasma protein bound
(8%) and that have high oral gut bioavailability (50%) [29,30].
In addition, it can be argued that the difference in sys-
temic exposure due to the lung versus gut can easily be
obtained using population PK modeling from the full expo-
sure study performed without charcoal, and therefore the
charcoal study could be avoided altogether because it is rela-
tively easy to discriminate, using a population approach, the
drug absorbed via the lung versus the gut [29]. For products
with a low gut bioavailability such as fluticasone (<1%) [28], the
systemic exposure anyways represents only the lung expo-
sure as exposure due to gut absorption is negligible. For these
products the charcoal study would provide essentially the same
results as the study given without charcoal. For drugs where
exposure due to gut absorption is expected to be significant
(e.g., exposure due to gut absorption accounting for let’s say
more than 20% of total exposure) such as albuterol [31], then
the plasma concentration–time profile will typically show very
clearly the dual absorption peaks with the first peak appear-
ing shortly after administration reflecting lung absorption and
a second peak appearing later reflecting gut absorption. Popu-
lation PK modeling can be performed to characterize the
exposure associated with the lung and gut absorption sepa-
rately, and determine if these different exposures are equivalent
between products. The use of this population approach was
previously reported by Auclair et al. [29]. While it is reason-
able for EMA to ask that PK equivalence be shown for lung
absorption only (with charcoal) as well as lung and gut ab-
sorption (without charcoal), this could all be calculated from
a single study without having to administer charcoal.
4.2. The need for dose–response for TE studies to be
robustly discriminative
TE studies with CE are currently required by the US FDA and
HC for a generic submission of OIPs. Based on the step-wise
Table 2 – Potential minimum study requirements for generic submission of Advair Diskus® DPI.
Advair Diskus® DPI
0.1/0.05, 0.25/0.05 or 0.5/0.05 of Fluticasone propionate (mg/inhalation)/salmeterol xinafoate (mg base/inhalation)
US FDA HC EU
Device similarity To the US marketed reference




– Number of doses
– Size and shape
– “Closed” device
Similar requirements as for the
USA but using the Canadian
marketed reference product (CRP)
Similar requirements as for the
USA but using the European
marketed reference product (ERP)
In vitro performance Must have similar in vitro
performance versus the URP:
– Equivalent emitted dose at 3
flow rates and beginning, middle
and end lifestages
– Equivalent aerodynamic particle
size distribution at 3 flow rates
and beginning and end
lifestages
Must have similar in vitro
performance versus the CRP
– Requirements similar to US ones
Must have similar in vitro
performance versus the ERP
– Requirements similar to US plus:
Dose linearity across all
strengths
Similar clinical safety Three Relative Bioavailability PK
studies showing equivalence in
terms of exposure for:
– High strength URP vs Test
– Mid strength URP vs Test
– Low strength URP vs Test
Two to three Relative
Bioavailability PK studies showing
equivalence in terms of exposure
for:
– High strength CRP vs Test
– Mid strength CRP vs Test (should
be able to be waived)
– Low strength CRP vs Test
No studies needed theoretically if
all in vitro comparability tests are
successful
In practice, a PK study with
charcoal on the low dose, and one
without charcoal on the high dose
are preferred despite passing all
in vitro tests
Similar clinical efficacy One TE study with CE showing
equivalence of URP with Test, and
superiority vs. placebo of both Test
and URP
Three way parallel study design
comparing Placebo, Test and URP
using CE after single and 4 weeks
of dosing in ~1000 patients with
mild to moderate asthma
One TE study with CE showing
equivalence of CRP with Test, and
superiority vs. placebo of both Test
and CRP
HC is slightly more flexible in their
specific design requirements than
the US, but the US requirements
should be acceptable theoretically
with the CRP. HC may accept TE
studies done with either URP or
ERP if equivalence to the CRP can
be demonstrated.
No studies needed if all in vitro
comparability tests are successful,
or if in vitro fails the dose linearity
for example but PK studies (some
with and some without charcoal)
indicate similarity across all
strengths
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approach, the EU would require such studies only when the
in vitro and/or PK studies do not show equivalence. A vital
element of a TE study with CE is the demonstration of a dose–
response relationship, in order to confirm that a lack of
difference in the CE is truly because the test and reference gen-
erate a similar level of effect, and not because the study lacks
sensitivity in detecting a difference.This has been amajor chal-
lenge, especially for products such as ICS, and is discussed
further below.
An ideal biomarker for aTE studymust possess several char-
acteristics. It must be clinically relevant, i.e., there must be a
link between the biomarker and the pharmacological mecha-
nism of the drug. It must also be objective, reproducible with
a reversible effect that is dependent on the dose [32,33].As such,
this would make it possible to establish a clear dose–response
relationship and apply the dose-scale approach that is favored
by the FDA [34]. A biomarker that is ideal for one drug may not
be ideal for another, as its relevance depends upon the drug’s
mechanism of action, and in some cases, there may be no ideal
biomarker at all. For example, forced expiratory volume in 1
second (FEV1) is a biomarker used to assess the response to
beta-2 agonists [18], and it is an ideal biomarker as it is re-
versible and related to systemic drug concentrations, thus it
exhibits a clear dose–response relationship.This biomarker has
been used now for approximately 20 years for submissions of
inhaled short-acting beta-2 agonists. FDA recently published
an individual BE guidance for the beta-2 agonist albuterol that
confirms its usage [18].
FEV1 may not be a good choice of a biomarker for ICS,
however, as it does not necessarily capture the dual mecha-
nism of action of these drugs. The response to ICS occurs in
two waves: the first response occurring on Day 1 after the start
of therapy and a latent response occurring 7 to 10 days later.
One of the major mechanisms behind the anti-inflammatory
effect of ICS in the treatment of asthma is via inhibition of the
effects of pro-inflammatory cytokines following binding with
glucocorticoid receptors [35]. By contrast, endocrine and meta-
bolic effects of corticosteroids are mediated through DNA
binding [35]. An ideal biomarker would be able to capture the
spectrum of responses to ICS and maybe not just the early or
late bronchodilatory response that is seen with FEV1. Regard-
less of this, fluticasone and the combination product
fluticasone/salmeterol have been approved by many diverse
regulatory agencies including the US FDA based on FEV1 mea-
sures. Because of this, the FDA has published an individual BE
guidance for the combination product fluticasone/salmeterol
and is asking generic sponsors to prove TE using FEV1 mea-
sures after single dose administration and after 4 weeks of
continued dosing [19].
Despite FDA issuing a BE guidance for the fluticasone/
salmeterol inhaler combination product, there is still a need
for a better biomarker for ICS response than FEV1 [36,37]. One
potential biomarker that used to be suggested for many years
by the FDA was exhaled nitric oxide (ENO). Although this
biomarker was hoped to reflect the secondary (latent) mecha-
nism of action of ICS, its response is influenced bymany factors,
such as collection techniques, disease states, and other patient
factors (food, drink, smoking) [38]. Even though there is still
some interest in using this biomarker for ICS [39], it is not nec-
essarily recommended anymore by regulatory agencies as
studies have revealed the absence of a dose–response rela-
tionship between ENO and fluticasone administered at the
marketed dosing regimens. The lowest labeled dose (88 mcg
twice daily (BID)) was associated with responses on or near the
plateau of the dose–response curve and responses did not return
to baseline levels after the 14-day washout period [40]. Others
have shown that ENO on its own cannot provide useful thera-
peutic information regarding response to ICS [41] or that it could
be useful as an adjunct to guide therapy [42].
HC was recommending the use of sputum eosinophils for
many years [25], believing that due to the presence of primed
eosinophils in airways that contribute to inflammatory pro-
cesses in asthmatics [37], this biomarker could characterize the
anti-inflammatory activity of ICS. No consensus appears to exist
though on the correlation between sputum eosinophils and ICS
response. Some researchers have found a positive relation-
ship between the two [43–49], while others have shown little
or poor correlation [50,51]. It is not clear if HC is still as opti-
mistic regarding this biomarker for ICS as in the past, as the
guidance document that contained it has been withdrawn from
HC’s website.
Although biomarkers such as FEV1 are generally accepted
to evaluate response to bronchodilators (short-acting and long-
acting beta-2 adrenoreceptor agonists) [18,26], it can be argued
that their utility for ICS response should be limited, because
similarly to ENO, the smallest marketed dosing regimen of
fluticasone, for example, results in a response that is already
at the top of the dose–response curve for FEV1.
Unfortunately no biomarker has been found or proposed
to date that would enable a dose–response to be seen across
themarketed doses of fluticasone inhalers or other ICS. Ideally
andassuming that anadequate biomarker could be found, thera-
peutic equivalence would have to be demonstrated by proving
that a dose–response relationship exists, otherwise the study
may not be discriminative at all if the doses studied are already
at the top of the response curve.The study should ideally include
a placebo and assess a low dose of the drug (the lowest dose
as recommended in the product labeling), aswell as a high dose
(generally 2 to 4 times higher than the low dose). For the study
to be valid, theoretically the response to the low dose of the
drug must be superior to the placebo, and the response to the
high dose of the drug must be greater than the response of
the lowdose. It is critical to be able to clearly distinguish between
responses to varying drug doses, otherwise it may be impos-
sible to distinguish reliably between drug formulations.
With the accumulated experience we now have concern-
ing the relationship between dose and response of PD
parameters such as FEV1 and ENO, simulations were made to
understand the importance of the existence or not of a dose–
response on the resulting power and alpha error of TE studies
with CE [52]. Using NONMEM®, thousands of TE studies each
with a 5-way crossover design (placebo, low dose test, low dose
reference, high dose test, high dose reference) were simu-
lated. Different scenarios (i.e., equivalent or non-equivalent
product, varying test to reference ratios) were simulated. Each
scenario included 1000 simulated TE studies, and each study
had a sample size of 136 subjects completing the 5 way cross-
over. Equivalence was assessed using the dose-scale approach
(Fig. 1), in which the equivalence is calculated on the dose scale,
and not on the response scale which is non-linear.
465a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 4 6 1 – 4 7 1
Simulations were performed when a dose–response truly
exists (e.g., the dose at which 50% (ED50) of the maximum effect
(Emax) is equivalent to the lowest dose marketed) and when a
dose–response does not exist, as in the case for ICS with FEV1,
as the ED50 is much lower than the lowest marketed dose.
Results of the scenario where the dose–response is present are
highlighted in Table 3. It can be seen that in the case where
ED50 occurs at approximately the low dose, such a TE design
has adequate power (>80%) to conclude equivalence with the
dose scale approach when indeed the products are
bioequivalent.When products are not bioequivalent, the alpha
error is slightly increased, 1 to 13.5% for a true test to refer-
ence ratio of 60 to 70%, but overall the products are shown to
not be equivalent.
Results of the scenario where the dose–response is not
present are highlighted in Table 4. This would be the case for
example for fluticasone using FEV1 or ENO as the CE using the
dose-scale, as the maximum effect is approximately seen with
the lowest dose marketed. Results show that any TE study in
this scenario using the dose-scale approach would have very
little power (<20%) to conclude equivalence even when the prod-
ucts are truly equivalent. Results show that it would be almost
impossible to prove equivalence and the method would not
really distinguish between a bioequivalent product and a non-
bioequivalent one, as the alpha error rates for non-bioequivalent
products are virtually the same as the statistical power for
bioequivalent products.
These results show the importance of an existing dose–
response at the doses studied in a TE study with CE when the
dose scale method is used. If the studied doses are at the top
of the response curve, then the dose scale method unfortu-
nately does not work and will almost never show equivalence
between a test and a reference formulation.
4.3. When using the dose-scale approach should one
study the high dose effect only for the reference or also for
the generic product?
As presented earlier, the dose scale approach is a good method
to assess TE in a study with CE when a dose–response truly
exists at the dosing regimens studied.We have seen in Table 3
that with this method, and in an appropriately powered study,
the power to prove equivalence is as expected when the test
and reference products are equivalent, while when not equiva-
lent the discriminatory power is also adequate although
resulting in a slightly higher alpha error than what we typi-
cally see with PK equivalence studies. Therefore this method
should be used whenTE studies with CE are performed versus
the alternative of creating ratios and confidence intervals on
the response scale which is not robust due to the non-linearity
of the response.
FDA’s recommendations for a few products requiring the
dose-scale approach are currently not always consistent. For
albuterol inhalers, FDA is recommending a 4-way instead of
a 5-way study [18]. These are obviously minimum recommen-
dations as a sponsor could always study more, but this study
design includes a placebo, low dose test, low dose reference,
and high dose reference. What is missing is the high dose of
the test. Although not absolutely needed, as the dose–response
curve can be assessed with reference doses only and equiva-
lence is assessed on the low dose, we aimed at discovering the
impact of including or not this fifth arm in these studies. Ten-
thousandTE studies with either 4- or 5-arm crossover designs
including 136 patients each and for five different scenarios
(three equivalent products and two non-equivalent products)
were simulated using NONMEM®. Results are presented in
Table 5 and indicate that the statistical power to prove equiva-
lence is as expected with the 5-arm design (approximately 80%),
while it becomes much lower (approximately 60%) when a
4-arm design is selected and the test is not administered as
a high dose. In order for the 4-arm design to be associated with
80% power, the study would have to include almost double the
Fig. 1 – Graphical representation of the dose scale approach
to assess TE.
Table 3 – Statistical power and alpha error of TE studies
when a dose–response does exist and when the dose
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number of patients. Doubling the number of patients in a 4-arm
study is much more complicated and costly than adding an
additional arm. Pharmaceutical companies should therefore
perform these studies as 5-arm designs instead of what is mini-
mally recommended.
4.4. The need for TE studies once PK equivalence is
demonstrated
Once a test and reference products are shown to be equiva-
lent based on comparative PK studies, we are presenting an
argument herein that TE studies using CE are no longer nec-
essary. The basis of this argument is that 1) TE studies are not
as discriminative as PK studies; 2) the lungs should not be con-
sidered a “topical” organ per se, as it is one of the most highly
perfused organ in the body because of its critical importance
in oxygenating the body; and 3) a drug product can only act
“locally” once it is in solution, not before, and once the API will
appear in solution at the site of activity in the lung then its
free drug concentrations should be immediately in equilib-
rium with the systemic circulation.
Daley-Yates and Parkins [53] summarized the in vitro, PK and
PD studies of several inhaled products, and concluded that there
was a lack of understanding between in vitro, PK and PD studies.
The authors mentioned an example of a product that was found
to be equivalent in terms of PK in one study [54], but not equiva-
lent in terms of efficacy (using FEV1) in another study (Kerwin
et al. [55]). This comparison between two studies is com-
pletely misleading though, because the efficacy study they
referred to (Kerwin et al. [55]) saw aligned differences between
PK and efficacy (i.e., when PK was different the efficacy was
different). All other examples presented in the review by Daley-
Yates and Parkins [53] showed that when PK was equivalent,
efficacy was always equivalent, but when PK was not equiva-
lent, efficacy was sometimes equivalent and sometimes not
equivalent.This suggests that comparisons made using PD data
when equivalence is assessed on the response scale lacks speci-
ficity and with the tools we are using to date (e.g., no dose–
response, proving equivalence with only one dose and with a
biomarker that may not reflect the wide efficacy of the OIP) it
may not allow for a meaningful product discrimination for the
assessment of equivalence and therefore one could argue that
the study does not serve any true scientific purpose. PK studies,
on the other hand are much more sensitive and specific to
detect differences between two products. The ultimate ques-
tion is, are OIPs acting “locally” within the lungs with their
systemic exposure unrelated to their theoretical exposure
therein? Lawrence et al.’s paper from 1998 [56] is often quoted
in this regard as offering evidence that much higher sys-
temic exposure of fluticasone following oral versus inhalation
dosing does not result in efficacy and therefore suggests that
fluticasone acts locally within the lungs with no equilibrium
with the systemic circulation. We will see that this conclu-
sion is incorrect in the next paragraphs.
The lung epithelium differs in cell type and thickness, with
diminishing thickness from the trachea to alveoli. Following
absorption via the inhalation route, an API reaching the lung
epithelium must first dissolve into a solution before it can act
at the site of activity. Therefore, the exposure of the API at the
site of activity in the lungs depends on the drug formulation
characteristics, as well as physiologic ones [57]. The lungs are
the most or one of the most perfused organs of the body and
these should not be considered as a topical site of absorption
like the skin [36] but rather an extension of the systemic ex-
posure because of this high perfusion. This permits drug in a
solution state at the site of activity in the lung to be almost
instantaneously distributed to the systemic circulation. This
explains why maximum concentrations are seen virtually im-
mediately in a few seconds and minutes after inhalation for
drugs that have high solubility within the lungs. For example,
in a previous study we have found that the absorption half-
life of levalbuterol via inhalation into the systemic circulation
in dogs was less than 2 minutes, virtually as fast as adminis-
tering the drug via the intravenous route (29). The observed
“total” systemic concentrations after lung absorption there-
fore should directly reflect the “active” unbound drug
concentrations within the lungs. Drugs absorbed by the gut (e.g.,
tablet formulation) are accessible to the lung but only “unbound”
drug will be available to be in equilibrium with the site of ac-
tivity in the lung. As mentioned earlier, many argue that only
local exposure from the lung is involved in the efficacy of
fluticasone when concentrations following inhalation versus
oral administrations are compared [56].This is an incorrect com-
parison because only “unbound” drug will equilibrate between
the systemic circulation and the site of activity in the lungs,
and therefore any comparison using total systemic concen-
trations (sum of fluticasone bound and unbound to plasma
proteins) after gut absorption will overestimate the exposure
reaching the lung and consequently overestimate the ex-
pected efficacy. This incorrect comparison can be shown with
fluticasone as presented by Lawrence et al. [56].
Fluticasone has an oral bioavailability that is less than 1%
and its plasma protein binding is reported to be 99% [28]. In
the study reported by Lawrence et al. [56], no efficacy was
Table 5 – Power of TE studies using the dose-scale approach with 4-arm (placebo, low dose test, low and high dose









Equivalent 100% 79.8% 60.7%
95% 73% 57.4%
90% 67.7% 54.5%
Non-equivalent 70% 24.3% 23.6%
60% 6.4% 10.6%
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observed with a 20 mg oral administration of fluticasone when
compared to 100 and 500 mcg inhalation administrations.This
was true even though systemic concentrations after oral ad-
ministration were 2 to 3 times higher than after the 500 mcg
inhalation administration. If we consider that total plasma con-
centrations after inhalation reflect the lung concentrations and
that only unbound plasma concentration (less than 1% as
protein binding is 99%) after oral administration reflects lung
concentrations, then the lung fluticasone exposure from the
oral administration was approximately 50 times lower than that
for the 500 mcg inhalation administration. In order to have
equivalent lung exposures with the 100 and 500 mcg inhala-
tion dose, the oral dose would have needed to be as high as
200 to 1000 mg instead of 20 mg. The importance of consid-
ering free drug concentrations and not total drug concentrations
is further presented in Fig. 2 for this particular fluticasone
example.
Fig. 2 clearly indicates that because fluticasone is 99% protein
bound, a systemic overall exposure (AUC) of 629 pg.h/ml after
inhalation dosing suggests that the AUC of fluticasone in so-
lution as free drug concentration at the site of activity in the
lung was also 629 pg.h/ml because only free drug can go from
the lung to the systemic circulation. On the other hand, ad-
ministering a 20 mg oral dose may result in a systemic
fluticasone AUC of 1230 pg.h/ml but only 1% of this is free drug
concentration, so a free AUC of only 12.3 pg.h/ml.Therefore an
exposure of only 12.3 pg.h/ml can reach the lungs in terms of
AUC. It is because only free drug concentrations are active and
equilibrate through membranes resulting in a tiny exposure
of fluticasone in the lung (e.g., AUC of 12.3 pg.h/ml) that a 20 mg
fluticasone oral dose was not efficacious in that study, not that
fluticasone is not active from the systemic circulation as sug-
gested [56]. Considering that the fluticasone AUC in the lung
would only be 12.3 pg.h/ml with the 20 mg oral dose, it is not
surprising that this dosing regimen was not efficacious as the
resulting AUC at the site of activity would be 10 times lower
than what would be achieved with the lowest fluticasone in-
halation dosing regimen of 100 mcg BID.
For other ICS products that have higher gut bioavailability
or low protein binding, systemic concentrations from gut ab-
sorption do present efficacy and this absorption from other
sites should not be ignored. For example, oral albuterol has
an oral bioavailability of 44 to 63% [30,58] and negligible plasma
protein binding at approximately 8% [59]. Orally adminis-
tered albuterol has been demonstrated to be efficacious in
asthma patients [60] with improved morning and evening FEV1
values comparable to inhaled salmeterol indicating that
albuterol administered orally was able to have an effect on
the lung.
The importance of protein binding on the efficacy of inhaled
drugs has been recognized by Wu et al. where the authors
showed that glucocorticoids with higher plasma and tissue
binding showed a reduced efficacy in the lung [61].
5. Future directions
5.1. Global harmonization and the pursuit of the global
worldwide reference product
We have seen that there is still more work to do for highly regu-
lated regions like the USA, Europe, and Canada to present and
enforce aligned regulations regarding OIPs. In this current global
economy, it would be very advantageous and less confusing
if regulatory bodies of highly regulated regions such as FDA,
EMA, and HC would present aligned regulations. There is a lot
of “gray” in scientific understanding (e.g., it is not “black or
white”) and regulations do follow science, so it is not surpris-
ing that opinions between regulators vary based on this level
of “gray”. It may be reasonable scientifically for EMA to suggest
performing PK equivalence studies with charcoal and without
charcoal, but then it may be reasonable for HC and FDA not
to request it as well.The same can be said for TE studies. Regu-
lators should grasp the opportunity to better align their
regulations and guidances based on an understanding of what
may be a common reasonable scientific position.
Fig. 2 – Fluticasone total AUC after oral and inhalation dosing cannot be compared directly; only free drug concentrations
will equilibrate between the lungs and the systemic circulation.
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Even more limiting, though, is the fact that FDA, EMA, and
HC have to ask generic pharmaceutical companies to assess
BE of their test product versus a reference product that is avail-
able in their own respective market. So theoretically even
though regulations and guidances would be perfectly aligned,
generic pharmaceutical companies would still need to perform
all studies versus the US reference product, versus an EU ref-
erence product, and again versus the Canadian reference
product. This is obviously not financially viable nor desirable
in regards to OIPs. Regulatory agencies do not share between
themselves submitted pharmaceutical company dossiers, pre-
venting them to assess if the reference product from one
country is identical to the one in theirs.This has been themajor
impediment toward declaring a “global worldwide reference
product” that generic pharmaceutical companies could use in
their development. It is however very likely that most of the
reference products marketed in highly regulated regions such
as the USA, Europe, and Canada are in fact the identical prod-
ucts, making the topic even more frustrating to not just generic
pharmaceutical companies themselves, but also to patients who
need to pay more for their generic drugs because of greater
development costs, and to regulatory agencies themselves who
would save time and money if they could share between them-
selves the review of these submissions.We would propose that
highly regulated regions such as the USA, Europe, and Canada
agree to accept studies with either the US, EU, or Canadian ref-
erence products if all of the different product labels of these
three reference products are quoting the exact same pivotal
Phase III studies to establish their safety and efficacy. When
this is the case, it then means that all of these marketed ref-
erence products had to be proven to be bioequivalent to the
formulation used in the pivotal Phase III trials, and therefore
they should by extension be bioequivalent between each other.
Harmonizing regulations and accepting more often studies
performed with a “foreign” reference product, or declaring a
“global worldwide reference product” in appropriate cases,
would bring more clarity to pharmaceutical companies, pa-
tients, and health care professionals as to what is required, and
encourage more companies to invest in the development of
products.
5.2. Drop of the requirement for TE studies if PK
study is successful
We have seen that the usefulness of TE studies is limited on
its own because of its very low discriminatory power when
equivalence is assessed on the response scale, or because of
its impossibility at assessing equivalence with the dose-
scale approach when the commercialized doses of the OIPs are
already all associated with effects residing at the top of the
response curve. TE studies for OIPs are prohibitively expen-
sive. A single TE study that follows the FDA guidance for a
generic formulation of Advair Diskus®, for example, may have
to enroll thousands of patients at an overall cost listed in the
7 figures. If this study was absolutely necessary to establish
clinical equivalence then it would be reasonable to perform.
But understanding that this study is not really discriminative
even if powered correctly, understanding that the systemic
exposure PK equivalence study is on the other hand discrimi-
native, and understanding that due to the high perfusion nature
of the lung the systemic PK exposure should reflect the free
drug PK exposure “in solution” at the site of efficacy in the lung,
then the conclusion is that TE studies should not be neces-
sary to establish BE once device, in vitro, and PK equivalence
are all established.
6. Conclusion
While there are many factors to consider with OIPs for local
action in comparison with orally administered drugs, it can be
argued that PK equivalence studies could be used to estab-
lish BE between such products without necessitatingTE studies
with CE. Although some have argued that systemic drug con-
centrations that are used in PK equivalence assessments do
not reflect drug levels or PK processes in the lungs, this is often
incorrectly based on total drug instead of free drug concen-
trations. Because of the high-perfusion nature of the lungs,
systemic exposure levels should be in equilibrium with and
adequately inform on what would be the free active drug in
solution at the site of activity in the lungs for OIPs.
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